Clinical Trial Update: Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of tesevatinib in autosomal dominant polycystic kidney disease (ADPKD) has completed with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adpkd
• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• tesevatinib (tesevatinib)

Snippet

Sponsor: Kadmon, a Sanofi Company | Conditions: Autosomal Dominant Polycystic Kidney, ADPKD | Phase 2 | Status: COMPLETED | Results posted: 2023-02-06